EACTS

Renibus Therapeutics Announces Oral Presentation on RBT-1 at the European Association for Cardio-Thoracic Surgery (EACTS) 2nd Innovation Summit

Retrieved on: 
목요일, 4월 18, 2024
Weill Cornell Medicine, Hospital, Risk, Doctor of Philosophy, EACTS, Quality, Pharmacist, FACS, ICU, Patient safety, JD, CABG, Patient, DSM-IV codes, Associate

Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery and Vice Chairman of Quality and Patient Safety, New York-Presbyterian Hospital, Weill Cornell Medicine, will be presenting on behalf of Renibus.

Key Points: 
  • Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery and Vice Chairman of Quality and Patient Safety, New York-Presbyterian Hospital, Weill Cornell Medicine, will be presenting on behalf of Renibus.
  • RBT-1 (stannic protoporfin / iron sucrose) is a single dose, multi-organ, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing elective cardiac surgery.
  • RBT-1 is actively enrolling in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery.
  • Details of the oral presentation at EACTS 2nd Innovation Summit:
    Presenter: Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine

The Future of Single Chamber ICDs: BIOTRONIK Takes Unprecedented Market Stance with Proprietary DX Technology

Retrieved on: 
월요일, 2월 12, 2024
DX, Page, Journal of Cardiovascular Electrophysiology, ESC, Risk, Atrial fibrillation, ICD, PMID, American College, REACT, Patient, EACTS, Task force, Molina Healthcare, Guideline, Diagnosis, Update, MATRIX, Medical device

"We are very proud that our DX technology provides the only lead available on the market offering both ventricular pacing/defibrillation and atrial monitoring," said Ryan Walters, BIOTRONIK US President.

Key Points: 
  • "We are very proud that our DX technology provides the only lead available on the market offering both ventricular pacing/defibrillation and atrial monitoring," said Ryan Walters, BIOTRONIK US President.
  • "Due to DX´s ability to provide additional patient and clinical benefits, it became clear to us that we should be using DX technology with every BIOTRONIK single-chamber ICD."
  • Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverter-defibrillator systems: Results of the SENSE trial.
  • REACT DX registry: Real world REACTion to atrial high rate episodes detected in implantable cardioverter-defibrillator recipients with a DX lead.

TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker

Retrieved on: 
목요일, 12월 21, 2023
SAS, University Medical Center, EACTS, NYHA, Patient, Heart failure, Female, Medical device

Paris, France and Munich, Germany, December 21, 2023 – TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the successful implantation of its Topaz transfemoral tricuspid heart valve replacement system (“Topaz”) in a patient with a pacemaker at the University Medical Center of Mainz, Germany.

Key Points: 
  • Paris, France and Munich, Germany, December 21, 2023 – TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the successful implantation of its Topaz transfemoral tricuspid heart valve replacement system (“Topaz”) in a patient with a pacemaker at the University Medical Center of Mainz, Germany.
  • Topaz is an innovative, minimally invasive device designed specifically to help patients suffering from severe TR, without the need for open heart surgery.
  • The Topaz device was implanted in a 74-year-old female patient with a pacemaker lead passing through the tricuspid annulus, classed as having New York Heart Association (NYHA) class III heart failure and presenting with torrential TR.
  • Two months later the patient came back for a follow-up visit which confirmed the excellent results of the Topaz implantation.

Jefferson Welcomes Internationally Recognized Cardiovascular Surgeon, Joseph E. Bavaria, MD to Enhance Heart and Vascular Program

Retrieved on: 
수요일, 11월 15, 2023
Thoracic aortic aneurysm, Jefferson Health, MPP, Tulane University, FACP, Society of Thoracic Surgeons, Interim, Cardiothoracic surgery, STS, Heart, Surgeon, EACTS, Hospital, Medicine, Thomas Jefferson University, Division, Master of Science, University, Diagnosis, Doctor of Philosophy, Society, Dentistry, MD

PHILADELPHIA, Nov. 15, 2023 /PRNewswire/ -- Jefferson is pleased to announce that Joseph E. Bavaria, MD is joining Jefferson Health and Sidney Kimmel Medical College, effective January 15, 2024.

Key Points: 
  • PHILADELPHIA, Nov. 15, 2023 /PRNewswire/ -- Jefferson is pleased to announce that Joseph E. Bavaria, MD is joining Jefferson Health and Sidney Kimmel Medical College, effective January 15, 2024.
  • Dr. Bavaria brings a wealth of leadership and surgical expertise to Jefferson's expanding team as it continues to advance the diagnosis, treatment and prevention of heart and vascular conditions.
  • "Dr. Bavaria's distinguished career in cardiovascular research and surgical advancements make him a valuable addition to Jefferson's expanding Heart and Vascular program," said Baligh Yehia, MD, MPP, MSc, FACP, President of Jefferson Health.
  • "This is a unique time to be joining Jefferson as the organization focuses on integrating cardiovascular services throughout the system.

iFR and FFR are equally safe to diagnose and treat heart disease according to largest-ever analysis of new real-world, long-term data

Retrieved on: 
목요일, 10월 26, 2023
Clinical Science (journal), Gold standard, European Society of Cardiology, AEX, Public sector banks in India, American College, Interventions, NYSE, INT, PHG, Pilot in command, ESC, Pressure, Lund University, Safety, Revascularization, American Heart Association, JACC, Risk, Guideline, MACE, PCI, Blood, FFR, TCT, Patient, Diagnosis, Death, EACTS, American College of Cardiology, Medical device, Pharmaceutical industry, Medical imaging, Cardiology

iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures.

Key Points: 
  • iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures.
  • The analysis, “Long-term Safety of Revascularization Deferral Based on Instantaneous Wave-Free Ratio or Fractional Reserve,” compares patient outcomes using iFR and FFR in the diagnosis and treatment of heart disease.
  • The cumulative MACE risks for each group differentiated by 1.6% (iFR: 21.5%, FFR: 19.9%, HR 1.09 (95% CI: 0.90-1.33 at 5 years).
  • iFR is considered the Gold Standard for hyperemia-free physiologic assessment for measuring pressure in diagnostic and interventional procedures [1,4].

Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin

Retrieved on: 
목요일, 10월 5, 2023
Annual general meeting, European Association for Cardio-Thoracic Surgery, NYSE, INR, Real, EACTS, Thrombosis, Warfarin, Patient, LOR, Aortic valve, Medical imaging

ATLANTA, Oct. 5, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its On-X Aortic Heart Valve Low INR post-market study presented in a Late-Breaking Science session at the 37th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Vienna, Austria. Real world interim results for all patients confirm that the On-X Aortic Valve remains safe and effective with low-dose warfarin.

Key Points: 
  • Real world interim results for all patients confirm that the On-X Aortic Valve remains safe and effective with low-dose warfarin.
  • Professor Aung Oo, Clinical Lead for Aortovascular Surgery at Barts Heart Centre, London, England, presented an abstract titled, Real World Experience of 510 On-X Aortic Valve Replacement Patients Treated with Low Dose Warfarin.
  • The abstract included at least 1-year and up to 5 years of clinical data on study participants, with median follow up time of 3.4 years.
  • Notably, the data reflected an improvement in outcomes compared to the On-X Aortic Low INR IDE Study (IDE Study) data first published in 2014.

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

Retrieved on: 
수요일, 9월 27, 2023
CABG, Percutaneous coronary intervention, Anticoagulant, International, Bleeding, Intraparenchymal hemorrhage, CET, Boehringer, Dabigatran, STAR, EACTS, Edoxaban, Acute coronary syndrome, International Star Registry, Cytokine adsorbing column, CTD, Research, AstraZeneca, Professional corporation, Eli Lilly, Clopidogrel, DOAC, Boehringer Ingelheim, Incidence, Bayer, Neurosurgery, International Safe Harbor Privacy Principles, Patient, Risk, European Heart Journal, Daiichi Sankyo, Blood, Rivaroxaban, Annual general meeting, Cytosorbents Corporation, United Kingdom, BMS, Cardiology, European Association for Cardio-Thoracic Surgery, Starship Enterprise, Trauma, Ticagrelor, ATR, Pfizer, Birth control, Pharmaceutical industry, Dentistry, Janssen, Aorta, Sanofi

The International STAR Registry captures high fidelity data on real-world clinical use and associated clinical outcomes using CytoSorb® for antithrombotic drug removal (ATR) in the acute hospital setting.

Key Points: 
  • The International STAR Registry captures high fidelity data on real-world clinical use and associated clinical outcomes using CytoSorb® for antithrombotic drug removal (ATR) in the acute hospital setting.
  • The STAR Registry, not to be confused with the completed U.S. and Canada STAR-T pivotal trial, is enrolling ahead of internal projections with plans for ongoing presentations at large, international conferences.
  • The first registry analysis entitled, “ Insights from the International Safe and Timely Antithrombotic Removal (STAR) Registry ” was presented at the EuroPCR conference in May 2023, the largest interventional cardiology conference in the E.U., attracting 11,500+ participants this year.
  • It also includes, for the first time, data on patients being treated with CytoSorb to reduce seven different antithrombotic medications.

EQS-News: Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt

Retrieved on: 
수요일, 6월 28, 2023
Moyamoya disease, Heart, NYHA, Suture, Tricuspid valve, CSI, Diabetes, Cardiac rehabilitation, EACTS, Echocardiography, LVEF, Health status of Asian Americans, Minerva, Valve, Infarction, Euronext Paris, Mitral regurgitation, Patient, Mitral valve, Risk, CEST, Annual general meeting, European Association for Cardio-Thoracic Surgery, Aix-en-Provence, III, Medtech, New York Heart Association Functional Classification, Safety, Urinary incontinence, Medical device

Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN

Key Points: 
  • Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN
    “We are excited to inform the specialist audience about the first successful procedure with our Epygon system,” said Dr. Christophe Giot, Vice President Clinical Affairs.
  • “Our device is the only biomimetic transcatheter cardiac mitral valve in development that mimics the native mitral valve and physiological blood flow.
  • The objective of the study is to evaluate the safety and efficacy of Epygon valve implantation at 30 days.
  • Affluent Medical anticipates presenting interim results from the first five patients of the Minerva pilot study at the Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in October 2023.

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Retrieved on: 
월요일, 4월 17, 2023
Moyamoya disease, Heart, NYHA, Mitral regurgitation, Suture, Diabetes, Hospital, Cardiac rehabilitation, EACTS, Echocardiography, Safety, Health status of Asian Americans, Clinical trial, Pathology, Minerva, Doctor of Philosophy, Infarction, Data, Incidence, MD, Patient, Risk, Mitral valve, WHO Global Preparedness Monitoring Board, Regulatory News Service, ISIN, Tricuspid valve, Death, Aix-en-Provence, III, Medtech, New York Heart Association Functional Classification, Urinary incontinence, Medical device, Dentistry, Medical imaging, Science

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Key Points: 
  • Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.
  • Very positive outcome at one month follow-up of the patient implanted with the Epygon mitral valve.
  • Less than 4% of patients with severe heart mitral insufficiency receive surgery, according to Affluent Medical estimates.
  • It is the only biomimetic cardiac mitral valve in development, mimicking the native mitral valve and physiological blood flow.

Affluent Medical : 2022 full year results and update on clinical activities under development.

Retrieved on: 
금요일, 3월 31, 2023
NYHA, Hospital, Marketing, EACTS, Anatomy, LVEF, Clinical trial, Pathology, Dispersive flies optimisation, Trial of the century, TAVI, Congress, MRI, Mitral regurgitation, Patient, Mitral valve, DPS, Regulatory News Service, ISIN, Tricuspid valve, Health, Death, Aix-en-Provence, III, Medtech, Disease, Safety, Urinary incontinence, Pharmaceutical industry, Medical device, Nursing

Affluent Medical : 2022 full year results and update on clinical activities under development.

Key Points: 
  • Affluent Medical : 2022 full year results and update on clinical activities under development.
  • Excellent interim results from the Optimise II pivotal study for the KaliosTM mitral ring and increase in the number of clinical centers.
  • New sources of financing to support the advancement of the three clinical studies and the next development steps.
  • On March 9, 2023, Affluent Medical announced the first successful clinical implantation of its Epygon transcatheter mitral heart valve in a patient in Italy.